Table 1.
Characteristics of the 1758 WIHS participants by HIV/ART status. Median (interquartile range) for continuous variables, n (%) for categorical variables.
| HIV- (n=507) | +HIV-ART (n=358) | +HIV+ART(n=893) | p-value | |
|---|---|---|---|---|
| Age | 41.3 (33.6–48.7) | 42.9 (36.3–49.6) | 44.9 (39.3–50.7) | <0.001 |
| BMI | 29.8 (25.4–36.0) | 28 (23.5–34.1) | 27.5 (23.5–32.3) | <0.001 |
| Waist Circumference (cm) | 95 (84.1–107.9) | 92.1 (79.9–105.7) | 91.5 (83.5–103.1) | 0.005 |
| ETHNICITY | ||||
| White (Non-Hispanic) | 44 (9) | 30 (8) | 118 (13) | |
| White (Hispanic) | 52 (10) | 35 (10) | 108 (12) | |
| Black (Non-Hispanic) | 306 (60) | 231 (65) | 472 (53) | 0.002 |
| Black (Hispanic) | 20 (4) | 12 (3) | 20 (2) | |
| Other (Hispanic) | 64 (13) | 41 (11) | 145 (16) | |
| Other1 | 21 (4) | 9 (3) | 30 (3) | |
| RACE | ||||
| Black | 326 (64) | 243 (68) | 492 (55) | |
| Other | 85 (17) | 50 (14) | 175 (20) | <0.001 |
| White | 96 (19) | 65 (18) | 226 (25) | |
| Diabetes Group | ||||
| Not determined | 24 (5) | 29 (8) | 29 (3) | |
| DM Case | 105 (21) | 70 (20) | 203 (23) | 0.006 |
| Diabetes free | 378 (75) | 259 (72) | 661 (74) | |
| Taken lipid lowering drug in the last 6 months | ||||
| No | 475 (94) | 334 (93) | 778 (87) | <0.001 |
| Yes | 32 (6) | 24 (7) | 115 (13) | |
| CD4 Count/ml3 | 378.5 (236.5–557) | 497 (324–695) | <0.001 | |
| HIV RNA Viral Load (cp/mL) | 5700 (582.5–31000) | 80 (80–120) | <0.001 | |
| ART | ||||
| PI | 544 (61) | |||
| NRTI | 871 (98) | |||
| NNRTI | 100 (11) | |||
| CCR5 Antagonist | 1 (0) | |||
| Integrase Inhibitors | 26 (3) | |||
| Efavirenz | 231 (26) | |||
ART indicates antiretroviral therapy; HIV- indicates HIV-uninfected; −HIV+ART, HIV-infected and not on ART; +HIV+ART, HIV-infected and on ART; PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, Non-nucleoside Reverse Transcriptase Inhibitor.
1
Other contains Asian/Pacific Islander, Native American/Alaskan and Other.